{"id":7211,"date":"2022-06-03T12:14:29","date_gmt":"2022-06-03T10:14:29","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/06\/220421_PR_MaaT_Pharma_INRAE_Partnership_VF-1.pdf"},"modified":"2022-06-03T12:14:29","modified_gmt":"2022-06-03T10:14:29","slug":"220421_pr_maat_pharma_inrae_partnership_vf-1","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/inrae-and-maat-pharma-build-on-the-success-of-their-long-standing-partnership-with-the-entry-of-drug-candidate-maat013-into-phase-3-clinical-trial\/220421_pr_maat_pharma_inrae_partnership_vf-1\/","title":{"rendered":"220421_PR_MaaT_Pharma_INRAE_Partnership_VF-1"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-7211","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n